Caveolin-1 is a protein (encoded by the CAV1 gene) supposedly harboring a protective effect against fibrosis. CAV1 rs4730751 single nucleotide polymorphism (SNP) AA genotype was initially associated with lower graft survival compared to non-AA. However, subsequent studies could not find the same effect. CAV1 rs4730751 SNP was investigated on 918 kidney donors. Multivariate Cox-model analyses were performed to evaluate risk factors for graft loss. Longitudinal changes on long-term estimated glomerular filtration rate (eGFRs) were evaluated with a linear mixed model. Histopathological findings from protocolled biopsies after 3 months post transplantation were also analyzed. Donor CAV1 rs4730751 genotyping proportions were 7.1% for AA, 41.6% for AC and 51.3% for CC. The AA genotype, compared to non-AA, was not associated with lower graft survival censored or not for death (multivariate analysis: HR = 1.23 [0.74-2.05] and HR = 1.27 [0.84-1.92]). Linear mixed model on longterm eGFRs revealed also no significant difference according to the genotype, yet we observed a trend. AA genotype was also not associated with a higher degree of fibrosis index on protocolled kidney biopsies at 3 months. To conclude, donor CAV1 rs4730751 SNP may impact on kidney transplantation outcomes, but this study could not confirm this hypothesis.
This seminal study has led to the evaluation of CAV1 SNPs involvement in various diseases, such as chronic kidney diseases 17 , pancreas transplantation 18 , Anti-Neutrophilic Cytoplasmic Autoantibody (ANCA) vasculitis 19 or cancers 20, 21 . However, the enthusiasm has been somewhat tempered by the controversies that have risen about the real impact of CAV1 SNPs in the field of kidney transplantation. Indeed, Ma and colleagues found opposite results, as the screening of 16 CAV1 SNPs (including rs4730751) in 1233 kidney transplants could not reproduce Moore's observations 22 . Recently, graft survival was also not associated with CAV1 rs4730751 SNP either from donors or recipients in two other cohorts 23, 24 .
Hence, considering these uncertainties, we carried out a study in a large-scaled cohort in order to evaluate the impact of donor CAV1 rs4730751 SNP on kidney transplantation outcomes, using a combined analysis of graft survivals, long-term estimated Glomerular Filtration rates (eGFRs) and histopathological data from systematic kidney biopsies.
Results
Study population and baseline characteristics. From the 1 st of January 2000 to the 31 st of December 2016, 918 donors for kidney transplantation were genotyped for the CAV1 rs4730751 SNP. Alleles A and C were in equilibrium according to the Hardy-Weinberg law (respectively p = 0.27 and q = 0.73). CAV1 rs4730751 AA, AC, and CC genotypes were observed in respectively 7.1% (n = 65), 41.6% (n = 382), and 51.3% (n = 471) of donors. All donors and recipients' demographical characteristics are summarized in Table 1 . There was no difference between AA and non-AA donors, or between their respective recipients. Median follow-up was 47.7 months (23.7-119.1).
Graft outcomes: survival estimates and Cox models. Using the Log-Rank test (Fig. 1) , no long-term difference was observed for graft survival -censored for death (GS-DC), nor for graft survival -non-censored for death (GS-DNC), between AA and non-AA genotype (p = 0.64 and p = 0.64 respectively). Using a Cox model for multivariate analysis ( www.nature.com/scientificreports www.nature.com/scientificreports/ (HR = 0.62 [0.44-0.86]). Considering GS-DNC, in addition to the above-mentioned risk and protective factors, the donor sex (male) was also found to be a risk factor (HR = 1.34 [1.06-1.70]).
As a secondary analysis, we tested if carrying an A allele was significantly associated with a higher risk of graft failure. CC versus non-CC donors and recipients were similar (Supplemental Table 1 ). Carrying an A allele was also not associated with a higher risk of graft failure in uni-or multivariate analysis: GS-DC HR = 0.97 [0.77- Table 2 ).
Post-transplantation outcomes: eGFR variations.
Given the normal distribution of eGFR, this variable was not transformed. According to the Bayesian Information Criterion (BIC), the best model relation between eGFR and time was linear. Using then a linear mixed model ( Fig. 2 ), longitudinal changes of eGFR according to the Modification of Diet in Renal Disease (MDRD) formula over time were compared between AA (n = 59) and non-AA donors (n = 764) (Supplemental Table 3 ). We used 4785 available values of eGFR for 823 patients with a median follow up of 4 years [1.98-7.96]. The model was adjusted on significant variables in univariate analysis, i.e. recipient sex, age, time on dialysis, Body Mass Index (BMI), previous transplantation, cold ischemia time and donor age. There was no significant difference according to CAV1 genotype on long-term eGFRs (fixed effect of AA genotype at 3 months post transplantation eGFR: 2.95 mL/min/1.73 m² [−0.87-6.77, p = 0.13] and fixed effect of AA genotype on slope: −0.62 mL/min/1.73 m² per year [−1.33-0.13, p = 0.10]). When comparing CC donors (n = 421) versus non-CC donors (n = 402), there was also no difference on long-term eGFRs (fixed effect of CC genotype at 3 months post-transplantation eGFR: 0.21 mL/min/1.73 m² [−1.79-2.21, p = 0.83] and fixed effect of CC genotype on slope: −0.13 mL/min/1.73 m² per year [−0.52-0.26, p = 0.51]) (Supplemental Fig. 3 ).
Post-transplantation outcomes: proteinuria. As a surrogate marker, we also tested if AA genotype impacted on proteinuria after transplantation. There were 7936 available values related to 695 patients with a median follow-up of 2.2 years [0.72-8.00]). Using a linear mixed model (Supplemental Table 4 ), longitudinal changes of urine protein/creatinine ratio were compared between AA donors (n = 47) and non-AA donors (n = 648). There was no significant difference on both baseline effect and slope effect according to CAV1 genotype for long-term urine protein/creatinine ratio. (Supplemental Fig. 4 ).
Post-transplantation outcomes: 3-months kidney biopsies.
As protocolled kidney biopsies at 3 months post-transplant were systematically analyzed according to Banff classification since 2007 25 , only data for the last 394 recipients were available. Those included 25 CAV1 AA and 369 non-AA donors. Over the tested parameters, only the proportion of globally scarred glomeruli was significantly different between AA and non-AA (4.80% versus 7.70%, p = 0.034). Of note, there was no significant difference between AA and non-AA for Banff lesions scores especially as regards markers of chronic injury, such as mesangial matrix expansion (mm score), glomerular double contours (cg score), interstitial fibrosis (ci score), or tubular atrophy (ct score). There was also no significant difference for IFTA score (Table 3) .
We also evaluated the impact of carrying an A allele (n = 208 CC and n = 186 non-CC) on kidney biopsies graded according to Banff criteria, and could not find any significant difference between the two groups (Supplemental Table 5 ) in particular for fibrosis.
Discussion
The objective of our study was to evaluate the donor CAV1 rs4730751 SNP involvement on kidney allograft outcomes. It is currently the only study which investigates precisely the association between CAV1 rs4730751 SNP genotype and its related phenotype, through large scale clinical data, biological outcomes, and histopathological analyses. First of all, we could not find any significant impact of this polymorphism on graft survival. Secondly, one of the major strengths of our study was that we performed a longitudinal analysis of eGFR values using a mixed model, as a surrogate marker of graft survival. Again, eGFR trajectories did not differ significantly according to CAV1 genotype. Nevertheless, we observed a trend of a higher slope decrease for AA donors, without statistical significance, which may be due to a lack of power. Finally, while using a standardized analysis with Banff classification, we could not find any significant difference on kidney fibrosis in 3-months post-transplant protocolled kidney biopsies.
Considering the previous attempts to test CAV1 rs4730751 SNP impact on kidney allograft survival, Moore et al. showed for the first time a deleterious effect of this SNP 11 , when tested on two independent cohorts, the Birmingham cohort (n = 785) and the Belfast cohort (n = 679). In both cohorts, rs4730751 SNP was associated with a higher risk of graft loss (multivariate analysis AA versus non-AA: HR = 1.77 [1.08-2.90] and HR = 1.56 [1.07-2.27]). Even with a small prevalence of the AA genotype in both cohorts (respectively 7.3% and 7.1%), the risk conferred by the described association justified the authors to recommend further investigations on CAV1 rs4730751 SNP. Indeed, the impact of caveolin-1 involvement in post transplantation outcomes could be supported with several mouse models. Knock-out mice for CAV1 exhibited higher degree of kidney interstitial fibrosis than control mice, after unilateral ureteral obstruction challenge 26, 27 . In a pro-fibrotic environment, with sustained TGFβ stimulation, caveolin-1 deficiency may be associated with an accelerated fibrotic process and impaired outcomes, as caveloae are supposed to internalize TGFβ receptor 13 . Moreover, caveolin-1 deficiency may also be associated with a different inflammatory response and a pro-fibrotic polarization of M2 macrophages after unilateral ureteral obstruction challenge in knock-out CAV1 mice compared to wild type 27 www.nature.com/scientificreports www.nature.com/scientificreports/ concerning CAV1 rs4730751 SNP, no in vitro or in vivo data are available regarding caveolin-1 functionality in patients harboring this particular intronic SNP. The study from Moore et al. presents several differences compared to ours which may explain the difference of results. First, fibrogenesis is a multifactorial process 16 , in which CAV1 is known to play a role. Indeed, CAV1 rs4730751 SNP is supposed to be involved in an accelerated fibrosis process due to impaired abilities of protection against pro-fibrotic injuries. After kidney transplantation, several events cause pro-fibrotic kidney damages, such as cold and warm ischemia times, rejection, infections like Polyomavirus-associated nephropathy, and immunosuppressive agents, especially calcineurin inhibitors 28 . Thus, there may be differences between our cohorts regarding pro-fibrotic injuries, which would explain the difference of results. Second, Moore et al. validated the CAV1 rs4730751 SNP impact on two independent cohorts, including both living and brain-deceased donors, compared to our single cohort, including only brain-deceased donors. Finally, this study provided data which may be more accurate to assess long-term results, as the independent cohorts had a median follow-up of respectively 81 (54-113) and 69 months, compared to 47.7 months (23.7-119.1) in our single cohort. Moore et al. provided also data on long term indication biopsies for allograft dysfunction 11 and showed that the main cause of graft failure in the AA donor cohort was interstitial fibrosis (13 graft losses among 22 AA donors), mostly related to chronic cellular rejection (n = 6/13). On the contrary, we presented data on 3-month protocolled post-transplantation kidney biopsies, which may be too early to assess differences considering kidney fibrosis. Also, even if we could not find any effect of this SNP in our cohort, we cannot exclude that its effect could not be observed because of the differences mentioned above. After Moore and coworkers study, other teams studied the impact of CAV1 rs4730751 SNP on kidney transplantation outcomes. Ma et al. presented data on CAV1 rs4730751 SNP from 1233 kidney transplantations from Afro-American (n = 675) and European American donors (n = 558) 22 . The prevalence for AA donors was 4.00% in Afro-American donors and 7.84% in European American donors. As in our study, AA genotype was not associated with a higher risk of graft failure, but the authors were able to show interactions between other CAV1 SNPs and APOL1 SNPs, in particular the CAV1 rs6466583 SNP. We cannot exclude in our study that interactions with other SNPs affecting CAV1 sequence are underestimated. Furthermore, in our cohort ethnicity could not be collected for both donors and recipients, due to French ethical issue 29 . This could be an underlying confounder, especially considering the impact of donor APOL1 genotype on allograft outcomes 1 . To compare Ma et al. study with Moore and coworkers work, the differences on survival could be due to the same reasons than ours, i.e. difference of pro-fibrotic injuries. Moreover, as in our study, the study from Ma et al. also had a lower median follow-up of 34.3 months (13.8-57.9) compared to Moore et al. 11 . It could have been interesting to provide surrogate markers, in particular long term eGFR, which would support the lack of impact of CAV1 rs4730751 SNP in their cohort. In the same way, Van der Hauwaert et al. could not find any impact on graft survival in a smaller cohort (475 kidney donors, AA genotype prevalence: 7.6%) 24 , however AA genotype exhibited a significant decrease in eGFR. As in the present study, information concerning ethnicity was missing which may interfere with the results. As Van der Hauwaert et al. 24 , our results may suggest an impact on eGFR decrease as there was a trend of a higher slope decrease, using a linear mixed-model, for AA donors compared to non AA. Considering the low frequency of the allele, the absence of significance may be due to a lack of power. Furthermore, even if we could not find any difference on interstitial fibrosis-tubular atrophy in 3-months kidney biopsies score, we observed a significant higher percentage of globally scarred glomeruli in AA donors compared to non AA donors. This may be in line with the results of the previous studies on CAV1 genotype 11, 24 , where AA donors related recipients, who had experienced a delayed graft functioning, had lower eGFRs at 3-months than non-AA donors related recipients, suggesting a decreased ability of renal recovery. In this study, AA genotype was also associated with several markers of fibrosis, with a higher risk of chronic allograft dysfunction 24 , interstitial fibrosis 24 or vascular fibrosis 11 . AA genotype was also associated with a higher proportion of recipient showing a significant proteinuria at 5 years post-transplantation 24 . Unfortunately we could not reproduce these results with a more powerful linear mixed model.
We only focused on donor CAV1 rs4730751 SNP effect, since evidence exists that the donor genetic background may impact on kidney transplantation outcomes 30 . Yet, considering that one of the major risk factor for graft loss in our population was graft rejection, which may be related also to the recipient genetic background, the interrelationship between donor and recipient genetic background could be relevant to investigate. Sluczanowska-Glabowska et al. provided data on the impact of allograft recipient CAV1 rs4730751 SNP in a cohort of 270 kidney recipients. The prevalence of AA genotype was 7.4% 23 . There was no difference between AA versus non AA recipients, regarding long-term serum creatinine levels, or fibrosis index on kidney biopsies. They could also not find any difference between AA and non-AA recipients considering survivals. However, given the AA sample size, these results are probably subject to a lack of power.
Considering all these elements, assessing the real impact of CAV1 rs4730751 SNP on kidney transplantation outcomes still remains a matter of debate. The first seminal study had a robust design and managed to observe an effect of this SNP on two independent large-sized cohorts 11 , whereas four other studies [22] [23] [24] , including ours, could not reproduce these results on strong outcomes such as graft survival. AA genotype may be associated with graft survival and an accelerated decrease of eGFR, but converging proof still remains to be produced. There may also be other specific fields of research in kidney transplantation, such as caveolin-1 genotype involvement in BK virus nephropathy, as the kidney tubular cells way of infection is thought to be caveolae-endocytosis mediated 31 . Targeting specific recipients, carrying pro-fibrotic risk factors, could also be one relevant field of research in the future.
Patients and Methods
Ethical statement. This observational retrospective study was performed according to the Declaration of Helsinki and the Declaration of Istanbul. No organs were procured from prisoners. As the French Biomedical Agency regulates the allocation system in France, every organ was allocated by the Agency and transplanted in Lille, France (Centre Hospitalier Régional, Lille). The protocol was certified to be in accordance with French Statistical analysis. First, a descriptive analysis of the patients' characteristics according to CAV1 genotype was conducted to identify possible differences. Continuous variables are expressed as means ± standard deviations or medians (interquartile ranges), as appropriate. Categorical variables are presented as absolute numbers and percentages. Comparisons were made using the Student's T test for quantitative variables and the Chi2 test for qualitative variables.
Second, the median overall survival and median follow-up times were estimated using Kaplan-Meier and inverse Kaplan-Meier methods, respectively. Between-group comparisons were performed using the log-rank test. Univariate followed by multivariable Cox analyses were performed to identify independent predictors of the death-censored graft survival and of the death-uncensored graft survival in two separate models.
The proportional hazard assumption was checked by log-minus-log survival curves plotting and by the scaled Schoenfeld residuals test for all covariates. When the log-linearity assumption was not met for continuous covariates, the variable was categorized in order to minimize the Bayesian information criterion (BIC).
Multivariate Cox model types were built by including all the covariates that were associated in univariate analyses, using a p < 0.20 threshold for selection, and suppressing redundant covariates. Characteristics which are known to impact long term survival were also maintained in the final multivariate models regardless of the univariate significance (i.e. recipient and donor age, sex, and BMI, cold ischemia time, donor cause of death, cause of ESRD, HLA mismatch and previous transplantation).
Third, a linear mixed model estimated by Restricted Maximum Likelihood was used to compare longitudinal changes in eGFR and urine protein/creatinine ratio according to CAV1 genotype over time, beginning at 3 months post transplantation. The CAV1 genotype was treated as a fixed effect associated to two random effects for baseline value and slope. If the dependent variable was not normally distributed, we considered a relevant transformation. We then chose the best fit model for eGFR variations over time on the basis of BIC values.
Univariable analyses were conducted using three effects for each variable: on baseline value, slope (interaction with time) and CAV1 genotype. Among these parameters, those which were not significant (p > 0.20) were removed. If the association on the slope was significant, the corresponding association on baseline value was also considered. Finally, the selected significant variables were further analyzed in a multivariate linear mixed model to determine those acting independently (backward selection procedure, p < 0.05). The normal distribution of random effect on intercept, random effect on slope, residuals and homoscedasticity assumption were graphically assessed. Finally, chronic allograft injury parameters assessed on the 3 months post-transplantation systematic kidney biopsies were compared between groups of AA and non-AA genotype patients.
All analyses were performed using the 3.5.1 version of the R software with "nlme" and "survival" packages.
